Core Insights - Northwest Kidney Centers collaborates with Outset Medical to enhance access to home hemodialysis through the integration of the Tablo Hemodialysis System [1][2][3] - The partnership aims to improve patient independence and quality of life by providing an intuitive and user-friendly dialysis solution [2][3][4] Company Overview - Northwest Kidney Centers is a nonprofit organization established in 1962, recognized as the first outpatient dialysis provider and currently the eighth-largest in the U.S., serving over 2,000 patients annually [5][6] - Outset Medical is a medical technology company focused on transforming the dialysis experience, with the Tablo system being FDA-cleared for use from hospital to home [7][8] Product Features - The Tablo Hemodialysis System operates using standard tap water and electricity, simplifying the dialysis process and eliminating the need for complex infrastructure [2][3] - It features a touchscreen interface, automated setup, and cloud connectivity, making it accessible for both patients and healthcare providers [2][8] Impact on Patient Care - The collaboration is expected to empower patients by providing a more sustainable and easier-to-learn dialysis option, aligning with modern lifestyles [3][4] - Patients who participated in the pilot phase reported increased engagement and confidence in their treatment due to the system's intuitive design [2][3]

Company Overview - Outset Medical, Inc. is a medical technology company focused on transforming the dialysis experience with innovative technology [3] - The company has developed the Tablo Hemodialysis System, which is FDA-cleared for use in various healthcare settings, from hospitals to home [3] - Tablo integrates water purification and on-demand dialysate production into a single system, enhancing operational efficiency and patient care [3] Market Presence - The Tablo system is trusted by over 1,000 healthcare facilities in the U.S. and has facilitated millions of treatments administered by thousands of nurses [3] - Outset Medical aims to empower healthcare providers to establish in-house dialysis programs, leading to improved operational, clinical, and financial outcomes [3] Upcoming Events - Management will present at the 23rd annual Morgan Stanley Global Healthcare Conference on September 10, 2025, at 7 a.m. Eastern time [1] - A live and archived webcast of the presentation will be available on the company's investor relations website [2]

Accomplished nursing executive to lead Outset's clinical education and support programs for the dialysis nursing community SAN JOSE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced Brittni McGill has been named to the newly created role of Chief Nursing Officer where she will apply her extensive nurse executive leadership experience to ...

Company Overview - Outset Medical, Inc. is a medical technology company focused on pioneering technology to reduce the cost and complexity of dialysis [4] - The company's flagship product, the Tablo Hemodialysis System, is FDA cleared for use in various settings, including hospitals and homes, representing a significant advancement in dialysis technology [4] - Tablo integrates water purification and on-demand dialysate production, functioning as a mobile dialysis clinic with two-way wireless data transmission and a proprietary data analytics platform [4] Financial Results Announcement - Outset Medical will release its financial results for the second quarter of 2025 after the market closes on August 6, 2025 [1] - A conference call will be held on the same day at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) to discuss the financial and operating results [2][3] - Participants interested in the conference call must register online to receive dial-in numbers and a unique pin [3]

Market Opportunity - The U S End-Stage Renal Disease (ESRD) market represents $73 billion in annual spending, with Medicare paying $41 billion[13] - Dialysis for ESRD patients accounts for 7% of the entire Medicare budget, while these patients comprise only 1% of the Medicare population[13] - The company estimates a $114 billion U S Total Addressable Market (TAM), including $25 billion for the acute and post-acute market and $89 billion for the home market[35, 38, 65] Tablo System Advantages - Tablo enables potential cost savings of 50% – 80% in acute dialysis, with a potential payback period of less than 1 year[49] - One customer projected net savings of $450,000 in the first year and estimated net savings of $550 per treatment using Tablo[52] - Tablo reduces dialysate preparation time to 0 hours, compared to 16–24 hours per week for historical devices in home care[72, 74] Commercial Traction - The company has trained >10,000 nurses and 1,000 physicians[59] - The company has secured contracts with 10 of the 10 largest subacute providers and 8 of the 8 top national health systems[56, 58] - The company has performed >1,000,000 treatments per year[11] Financial Position - The company estimates a cash position of $210 million entering 2025[90] - The company secured $169 million in gross proceeds from a January 2025 equity financing[90] - The company has recurring revenue of >60%, which is expected to grow over time[85]